Articles tagged with Antibodies
Researchers have developed an effective antibody against radiation-induced pulmonary fibrosis, a debilitating side effect of lung cancer treatment. The antibody targets connective tissue growth factor (CTGF), reversing fibrotic transformation and improving pulmonary function in mice.
Researchers developed a new treatment pathway removing antibodies from the bloodstream to reduce chronic infections and hospital stays. The approach showed positive outcomes for two patients with resistant Pseudomonas aeruginosa lung infections.
A new fluorescent probe developed by Michigan Technological University researchers has the potential to improve cancer surgery outcomes. The probe uses a near-infrared fluorescence that can penetrate deep tissues, reducing background noise and increasing precision for surgeons.
Researchers at Boston Children's Hospital report achieving strong vaccine responses in newborn animals and monkeys using a new adjuvant formulation. The study demonstrates the potential for a single-dose vaccine to protect against life-threatening infections, promising to reduce infant mortality globally.
Researchers at Uppsala University have discovered that antibodies against cartilage protein collagen II are associated with a good prognosis in rheumatoid arthritis. The study found that patients with these antibodies showed increased signs of inflammation during the first six months after diagnosis, but no difference later on.
Researchers developed a new drug delivery method using antibody-drug conjugates (ADCs) that show high precision and stability. The method successfully treated hard-to-treat solid and liquid tumors, including HER2 breast cancer and CD138 multiple myeloma, without harming healthy cells.
A lab study identifies mutations in hepatitis C virus that evade the natural immune system and vaccines, highlighting a major barrier to vaccine development. Researchers found that these mutations occur outside of traditional vaccine targets and confer resistance to commonly used antibodies.
A new study found that an antibody targeting CD47 can effectively treat five types of pediatric brain cancer in mice, with no harm to healthy brain cells. The treatment, developed at Stanford, has shown promising results in preclinical trials and is expected to reach clinical trials in children with brain cancer in one to two years.
Researchers have developed a new method to create antibodies with consistent sugar groups, enhancing their ability to signal the immune system. This breakthrough could lead to more effective therapies for cancer and autoimmune diseases, with the potential for customized antibody production.
Researchers at University of Utah Health Sciences found that a common yeast species exacerbates Inflammatory Bowel Disease (IBD) symptoms in mice. Allopurinol, a generic drug, showed promise in reducing inflammation and potentially offering relief to patients with high yeast antibodies.
A new study reveals that patients with pre-existing donor-specific antibodies experience better kidney survival rates compared to those with de novo antibodies. Understanding the timing of antibody responses can guide matching and prevent rejection.
A Japanese research group has identified a newly-identified autoimmune endocrine disease caused by thymomas, which leads to hypopituitarism. The study found that abnormal expression of PIT-1 in thymoma cells triggers immune tolerance breakdown, resulting in autoimmunity.
By using an antibody-based technique, scientists inactivated GluA1 receptors at synapses, temporarily abolishing fear memory in mice. The researchers found that inactivation of GluA1 up to 2 hours after a fear-learning task resulted in the loss of fear memory.
A team from the University of Pennsylvania identified circulating helper immune cells in blood after an annual flu vaccine, tracking their contribution to antibody strength. The study found that these cells play a crucial role in antibody development and could inform future vaccine design.
A research group at Kobe University has discovered a potential new cancer treatment that activates cancer-engulfing cells. The treatment uses an antibody to activate macrophages, which can effectively eliminate cancer cells. This discovery could lead to the development of new and more effective cancer treatments.
A study at Technical University of Munich found that antibodies can activate human nerve cells within milliseconds, modifying their function. This knowledge improves understanding of illnesses associated with certain types of cancer and paraneoplastic syndromes, which occur when the body's autoimmune reaction attacks its own cells.
A new study found that abnormal antibody production in the intestine of people with HIV-1 may lead to chronic inflammation and AIDS despite treatment. The research revealed that immune system cells in the intestines have decreased capacity to produce mature antibodies.
A study led by NYU Langone researchers identified CD99, a protein-sugar molecule, as a potential therapeutic target for blood stem cell cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Antibodies against CD99 can selectively kill cancer stem cells while sparing normal blood stem cells.
Researchers at UNC have engineered platelets to carry cancer-fighting antibodies, allowing them to target and kill microtumors before they can grow or spread. This innovative approach has shown promising results in animal studies, potentially offering a new hope for patients with recurring cancer after surgery.
A UCF researcher has developed a method that uses nanoparticles and Faraday rotation to measure protein quantities in test solutions, allowing for faster biochemical immunology test results. This technique could lead to faster diagnoses for HIV, Lyme disease, syphilis, and other infectious conditions.
Researchers at UM SOM and SOD published 22 articles on infectious agents, vaccines, and immune system activation. Studies focused on Ebola, Clostridium difficile, biofilms, and other topics, advancing knowledge in infection and immunity research.
Researchers at Uppsala University developed a new antibody design that increases brain uptake of antibodies almost 100-fold, offering new opportunities for treating brain diseases. The modified antibodies use the transferrin receptor to transport them across the blood-brain barrier.
WPI researchers develop a liquid biopsy chip that can trap and identify metastatic cancer cells in small amounts of blood. The device uses antibodies attached to carbon nanotubes, which create an electrical signature that can be detected to identify captured cells.
A study found that patients with oropharyngeal cancer who recur have higher levels of antibodies for proteins E6 and E7, which can detect recurrence before it's diagnosed. This biomarker could provide an early window for treatment.
Researchers at the University of Birmingham found that antibody levels in saliva are linked to those in blood serum, suggesting a non-invasive method for assessing immunity. Higher antibody concentrations in serum were associated with higher concentrations in saliva, particularly for IgA antibodies.
Researchers developed a vaccine that stimulates an antibody targeting pathological tau, discovering its Achilles' heel. The antibody avoids immune reaction towards the body by coupling to a carrier molecule.
Research shows that blocking type I interferon signaling can enhance the effectiveness of antiretroviral therapy (cART) in HIV-infected mice. By targeting IFN-I signaling, antibodies were able to reduce chronic immune activation and viral load, leading to improved infection management.
A new study suggests that blood-borne HPV antibodies can serve as a reliable biomarker for predicting the outcome of all types of head and neck cancer. The researchers found that patients with an immune response to HPV have a lower risk of dying during the five-year follow-up period, regardless of the exact location of their tumors.
ADC MI130110 shows remarkable antitumoral activity in CD13-expressing tumor cells, impairing tubulin polymerization and disrupting the microtubule network. The treatment resulted in significant reduction in tumor size, complete remission, and increased median survival time.
Scientists have created peptide probes that attach to proteins with comparable efficiency to antibodies, improving image resolution. These probes can help shed light on protein layout and quantification, opening new possibilities for neurobiological research.
Researchers at Duke University have developed a new PEG delivery system that avoids immune responses and extends the duration of drugs in the bloodstream. The technology, which produces more uniform results, shows excellent efficacy in controlling glucose levels in diabetic mice.
Researchers at Duke-NUS Medical School have discovered how the human antibody C10 prevents Zika infection by locking proteins into place, preventing viral DNA entry. Disrupting fusion with C10 may be more effective than targeting docking in preventing Zika infection.
Researchers found that 2-dose HPV vaccine regimens for girls and boys aged 9-14 years had noninferior antibody responses compared to 3-dose regimens for adolescent girls and young women. The study suggests using a 2-dose schedule could improve adherence to HPV vaccination programs and reduce healthcare costs.
Researchers at Georgia Institute of Technology enhance atomic force microscopy by adding electronic white noise to detect molecular interactions in slow motion. This improvement allows for the measurement of varying shades of gray, enabling a more detailed understanding of molecule binding and unbinding.
Researchers at UT Austin report that conventional flu vaccines may not be effective, and a new class of antibodies could protect against multiple strains. The study discovered a new approach to identifying and quantifying antibodies in human blood, allowing for more precise understanding of vaccine efficacy.
Antibody drug conjugates (ADCs) have shown efficacy and acceptable toxicity, surpassing radionuclide conjugates in certain tumor types. Targeting cancer stem cells may further improve treatment outcomes.
A 75-million-year-old Mongolian oviraptor fossil preserved the original keratinous claw sheath that covered its digits. The study adds to evidence that organic materials can preserve over time, revealing details about how proteins might be preserved.
A mouse study found an antibody can soothe raging, nerve-driven poison ivy itch by blocking an immune system protein. The researchers also discovered that blocking another receptor for the protein alleviates itch, paving the way for potential treatments.
Researchers have identified a human antibody that prevents Zika virus infection in pregnant mice and protects adult mice. The antibody also prevented damage to the placenta and fetuses, suggesting it may be used to prevent Zika-related birth defects.
Scientists developed two types of llama antibody that can specifically mark and show amyloid plaques and neurofibrillary tangles, the characteristic lesions of Alzheimer's disease. These antibodies have the rare ability to cross the blood-brain barrier, allowing for non-invasive detection.
Researchers found that the key viral protein used in candidate HCV vaccines is surprisingly flexible, elicit a wide variety of antibodies that cannot block viral infection. This flexibility may be why current vaccines have been ineffective in preventing HCV infection.
Scientists at the University of Basel discovered that chronic viral infections lead to an inadequate immune response due to prolonged inflammation. This hasty reaction by B cells produces antibodies quickly but also leads to their rapid depletion, resulting in a short-lived and unsustainable defense against the virus.
Three different candidate Zika vaccines have been found to protect rhesus monkeys against the disease in trials. The vaccines, tested in preclinical trials, were found to be effective at warding off infection by the Zika virus strain circulating in Brazil and Puerto Rico.
Researchers at Michigan Technological University provide a detailed overview of Zika's history, transmission modes, and risks, including sexual transmission and miscarriage risks. The study also highlights the connection between dengue virus infection and Zika virus exacerbation.
A new device uses a forest-like array of vertically-aligned carbon nanotubes to selectively trap viruses by size, increasing sensitivity by over 100 times. This technology can capture unknown viruses without antibodies or sequence information, enabling early detection and potential vaccine development.
Research on therapeutic antibodies for spinal cord injury reveals potential applications in myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction. Several antibodies are reviewed as reagents to promote neurite outgrowth and inhibit immune responses.
Scientists have developed a two-pronged antibody that can counteract the unique immune-evasion mechanism of filoviruses like Ebola. The antibody, called a 'Trojan horse' antibody, targets the glycoprotein on the outside of the virus and prevents it from associating with a specific host-cell receptor in the endosome.
Developed by an antibody that blocks clot formation without triggering bleeding, the new blood thinner could be used to treat patients with heart and vascular diseases. Researchers also created a second antibody to rapidly reverse its effects, addressing safety concerns.
Activated B cells play a crucial role in the formation of immune memory, with some cells persisting for months after initial exposure. The study reveals that while plasmablasts dominate early responses to infections or vaccinations, activated B cells take center stage later on.
Researchers found that naturally infected chimpanzees developed antibodies able to neutralize multiple AAV serotypes, a hurdle for gene therapy. The study provides insights into the immune response to natural AAV infection and its implications for gene delivery strategies.
Two vaccine candidates have shown complete protection against the Zika virus in rhesus monkeys, with no adverse effects observed. The findings, published in the journal Science, provide a promising lead for developing a safe and effective human vaccine to combat this mosquito-borne disease.
Researchers found that adding anti-PCSK9 antibodies to existing treatments can significantly reduce LDL cholesterol levels in patients. The studies demonstrated a reduction in LDL cholesterol and achieved high response rates for both alirocumab and evolocumab.
Researchers at WashU Medicine have identified six antibodies capable of protecting against Zika virus infection in mice, providing crucial information on how these antibodies interact with the virus. The discovery could lead to the development of a vaccine, diagnostic tests, and potentially new therapies for Zika-related diseases.
Researchers tested serum antibodies from Ebola survivors and found substantial cross-reactivity with other filoviruses, suggesting long-lived immunity. The study's results indicate that antibody responses extend beyond the primary virus, imparting at least partial immunity to other filoviral infections.
A team of researchers has identified the mechanisms behind excessive antibody production in chronic infections, discovering a link between B-cell activation and type 1 interferons. Proteins like endosomal TLRs trigger proinflammatory responses, leading to increased B-cell antibody production and potentially exacerbating conditions.
Researchers at Osaka University identified a human immune receptor that detects pathogenic microorganism invasion, which recognizes cleaved antibodies and fights immune evasion mechanisms. This discovery contributes to the development of new treatments and prevention strategies against infectious diseases.
La Jolla Institute researchers reveal a powerful arm of the immune system that drives maturation of helper T cells. Their study identifies activin A as a key factor, which could lead to more potent vaccines and treatments for autoimmune diseases.
A study from Imperial College London found that previous exposure to the dengue virus may increase the potency of Zika infection, potentially leading to more severe symptoms. The research suggests that the Zika virus uses the body's own defences as a 'Trojan horse', allowing it to enter human cells undetected and replicate rapidly.
Researchers have discovered two antibodies that can efficiently neutralize both dengue and Zika viruses, sharing identical binding sites on their viral envelopes. This breakthrough could lead to the development of a single vaccine offering protection against both diseases.
Scientists at Helmholtz Zentrum München have developed a novel antibody targeting carbonic anhydrase XII, which is overexpressed in cancer cells, with the goal of improving treatment options for glioblastoma patients. The antibody conjugated with lutetium-177 can deliver lethal doses to tumor cells directly.